)
Visual
test
Orexo
Orexo (ORX) investor relations material
Orexo Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary5 Feb, 2026
Executive summary
Completed divestment of all US rights to Zubsolv to Dexcel Pharma for USD 91 million plus inventory, with potential earn-out up to USD 16.8 million based on 2026-2027 sales, and transition support agreements in place.
Strategic focus shifts to the AmorphOX technology platform and pipeline development, with investment in proprietary and partnered projects.
Transition phase with Dexcel includes support services, organizational adjustments, and gradual resource reduction through 2026.
R&D pipeline prioritized, with key projects OX640, OX124, OX390, and Izipry advancing toward clinical milestones and regulatory filings.
Adjusted 2025 financial objectives met, achieving positive EBITDA when excluding the Zubsolv transaction.
Financial highlights
Net proceeds from the Zubsolv sale totaled SEK 813.6 million after transaction costs, boosting year-end cash to SEK 912.4 million and restoring shareholder equity to SEK 491 million.
Discontinued operations contributed SEK 840 million to net earnings, mainly from the Zubsolv sale, with a profit on sale of SEK 769 million.
EBITDA for continued operations was negative SEK 70 million for the quarter; full-year EBITDA positive at SEK 3.2 million.
Continued operations Q4 net revenues were SEK 3.3 million, with EBIT of SEK -103.2 million.
Cash and cash equivalents at year-end: SEK 912.4 million, up from SEK 123.3 million.
Outlook and guidance
2025 outlook metrics (excluding Zubsolv transaction effects) were met: Zubsolv net sales USD 50.8 million, OPEX SEK 467.6 million, and positive EBITDA of SEK 3.2 million.
2026 priorities: advance AmorphOX platform, initiate pivotal OX640 trial, analyze OX390 in-vivo data, resubmit Izipry to FDA, and expand peptide/vaccine programs.
R&D expenses for 2026 will depend on clinical trial timing; guidance to be refined as plans solidify.
Runway of at least two years expected, with potential extension through partnerships or accelerated development.
Focus on securing new partnerships and cost coverage for ongoing and future projects.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 5 FebNESTE
EBITDA and cash flow surged in 2025, driven by operational gains and renewables growth. - 5 FebLSPD
Revenue and gross profit rose, margins improved, and guidance was raised for fiscal 2026. - 5 FebTPR
Record revenue, margin expansion, and raised outlook, led by Coach's 25% sales growth. - 5 FebCARR
2026 outlook projects stable sales and profit, led by commercial, data center, and aftermarket growth. - 5 FebVRLLOG
Stable profit, ₹5 interim dividend, and 1:1 bonus share issue approved. - 5 FebGLAD
Net investment income was $11.3M as portfolio value and credit capacity expanded. - 5 FebALCO
Land sales and leasing drove improved profitability and strong cash flow amid citrus exit. - 5 FebHDD
Net sales up 6.1% and EBITDA margin improved; FY2025/26 guidance reaffirmed amid headwinds. - 5 FebSLQT
Revenue up 12% to $537.1M, net income $69.3M, and new $415M credit facility boosts flexibility. - 5 Feb2371
Revenue up 21.5% YoY, profit down on higher investments; growth focus continues.
Next Orexo earnings date
R&D Day24 Mar, 2026
Orexo
Next Orexo earnings date
R&D Day24 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Orexo AB, a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States. The Company's strategy is to focus on developing products that reduce the risk of opioid dependence, misuse and accidental ingestion by chronic pain patients in need of effective pain management for long-lasting pain, who have been historically underserved. Furthermore, the company is differentiated by their scientifically-validated medications that treat lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The company's mission is to improve the lives of patients through acquisition, development and commercialization of new therapies as quickly as possible, with a focus on digital health technologies to rapidly deliver greater access to leading edge therapies.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage